FOLH1 and prostate cancer: Sufficient PSMA uptake on PSMA PET/CT is a crucial parameter to consider therapy, and since a significant fraction of prostate cancer patients with high PSMA PET/CT tracer uptake do not respond to PSMA-RLT, other parameters, which are not clearly identified yet, obviously play also a relevant role.